Gamma Irradiation in the Pharmaceutical Manufacturing Environment - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gamma Irradiation in the Pharmaceutical Manufacturing Environment
The author reviews the benefits, challenges, and considerations to be made when selecting a gamma-irradiation sterilization method.


Pharmaceutical Technology
Volume 34, pp. s40-s43

Final, filled products

Terminal sterilization covers all handling stages of the product. Irradiation also provides a documented, high SAL (such as 10-6 ) just as it can for medical devices (1–3, 6). Because final, filled products can be in liquid or suspension form, they need to be evaluated thoroughly (9, 10). Some basic observations from personal experience as well as published sources (4, 7, 9, 10) provide a starting point for evaluating materials:

  • Liquids are more difficult to irradiate than dry powder. Liquids may undergo pH changes if not buffered. They provide easy mobility to any reactive species created from the ionization process. Irradiation, as discussed earlier, creates ionization events or free radical formation. In a liquid state, these charged species can move freely throughout the solution and create more damage than in the limited-mobility dry or solid state. They also can be quite dense, resulting in wider dose distributions.
  • When free radicals are created, they do not remain free for long. The net effect may be scission to smaller polymers or cross-linkage to longer polymers, additions, and deletions that must be evaluated for safety, efficacy, potency and byproducts.
  • In general, proteins are less stable then many other compounds.
  • Aromatic rings (alternating double bonded structures) are more stable than aliphatic materials.
  • Heparin, steroids, antibiotics, and vitamins in dry form have been gamma irradiated successfully.

Available literature also suggests ways to improve the results of an irradiation-sterilized product (4, 7, 9, 10):

  • Transform liquids into solids to reduce free radical mobility and to increase the likelihood of a recombination event rather than a scission or cross-linkage. In many cases, even a product that is stable at room temperature can be frozen for the irradiation process by being irradiated in the presence of dry ice.
  • Consider adding free radical scavengers or antioxidants. The amounts and acceptability of the chosen compound need to be determined for the specific formulation, but the addition can affect the success of an irradiation process (e.g., ascorbate, Vitamin E).
  • Purge the filled product of oxygen by overlaying it with an inert gas such as argon or nitrogen. This process reduces the available oxygen and limits the reactions, requiring it to be present.
  • Keep the radiation dose as low as possible. Current published dose setting standards (The Association for the Advancement of Medical Instrumentation's guides 11137:2006, TIR 33, and TIR 40 provide options for relatively low minimum doses that still provide a high SAL) (1–3).
  • Work with a good microbiology laboratory to determine methods for properly quantifying total viable contamination level (bioburden). This point is especially important because the higher the estimated bioburden, the higher the minimum sterilization dose will be. Dilution factors and low-extraction efficiencies, for instance, can increase a low or nonexistent bioburden significantly. Because measured bioburden level can directly impact required minimum doses for sterilization, this value must be accurate (i.e., not inflated) to avoid the use of a higher dose than needed for sterilization.
  • Develop a relatively tight dose range for irradiation. Remember that a dose is always a range. This range includes the minimum dose required to give the SAL desired (or required) but also a maximum dose allowable for the product to be sterile as well as safe and effective. Supporting a tight dose range requires working closely with the contract irradiator to determine capabilities and may include modifications to carton sizes, density, or the number of cartons processed per carrier in an irradiator. Many factors affect the dose range that can be provided, so one must discuss the capabilities of the facility that will process the product before finalizing the dose range. Working together and starting early are critical to success.
  • Pay attention to timing. If the product contains material capable of supporting microbial growth, the time between manufacture and sterilization will affect the required dose.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here